Page 116 - Haematologica - Vol. 105 n. 6 - June 2020

F. Ravandi et al.
Haematol. 2014;27(1):39-52.
18. Sanz MA, Fenaux P, Tallman MS, et al.
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630- 1643.
19. Kumana CR, Au WY, Lee NS, et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol. 2002;58(8):521-526.
20. Au WY, Kumana CR, Kou M, et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood. 2003;102(1):407-408.
21. Au WY, Kumana CR, Lee HK, et al. Oral arsenic trioxide-based maintenance regi- mens for first complete remission of acute promyelocytic leukemia: a 10-year follow- up study. Blood. 2011;118(25):6535-6543.
22. Gill H, Yim R, Lee HKK, et al. Long-term outcome of relapsed acute promyelocytic
leukemia treated with oral arsenic trioxide- based reinduction and maintenance regi- mens: A 15-year prospective study. Cancer. 2018;124(11):2316-2326.
23. Siu CW, Au WY, Yung C, et al. Effects of oral arsenic trioxide therapy on QT inter- vals in patients with acute promyelocytic leukemia: implications for long-term car- diac safety. Blood. 2006;108(1):103-106.
24. Zhu HH, Wu DP, Jin J, et al. Oral tetra- arsenic tetra-sulfide formula versus intra- venous arsenic trioxide as first-line treat- ment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013;31(33):4215-4221.
25. Qian L. Phase II clinical trial of compound Huangdai tablet in newly diagnosed acute promyeocytic leukemia. Chin J Hematol. 2006;27:801-804.
26. Zhu HH, Wu DP, Du X, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non infe-
riority, randomised phase 3 trial. Lancet
Oncol. 2018;19(7):871-879.
27. Brunauer S, Emmett PH, Teller E.
Adsorption of gases in multimolecular lay-
ers. J Am Chem Soc. 1938;60(2):309-319. 28. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modifi- cation of the International Working Group (IWG) response criteria in myelodysplasia.
Blood. 2006;108(2):419-425.
29. Platzbecker U, Fenaux P, Adès L, et al.
Proposals for revised IWG 2018 hematolog- ical response criteria in patients with MDS included in clinical trials. Blood. 2019;133 (10):1020-1030.
30. Levaquin (levofloxacin) [Prescribing Information]. Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2008. https://www.accessdata.fda.gov/drugsatf- da_docs/label/2008/021721s020_020635s5 7_020634s52_lbl.pdf. Accessed 13 May 2019.
1574
haematologica | 2020; 105(6)